Uncoupling toxicity from therapeutic effect lies at the foundation of the current state of the
field of cutaneous immune‐related adverse events to immune checkpoint inhibitor therapy …

Cutaneous immune-related adverse events are frequently associated with immune
checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal …

Immune checkpoint inhibitors (ICI) induce T-cell-mediated antitumour responses. While ICI
were initially successfully applied in metastasized melanoma, they are now approved for …

Background: This study aimed to define the clinical characteristics, diagnosis and
management of pembrolizumab-induced BP and identify potential differences between …

Pemphigus und Pemphigoid sind seltene Autoimmunkrankheiten der Haut mit potenziell
lebensbedrohlichem Verlauf. Autoantikörper gegen epidermale und junktionale …

Background: Immune checkpoint inhibitor–induced pancreatic injury (ICI-PI) ranges from
asymptomatic hyperlipasemia to symptomatic acute pancreatitis (AP). The proportion of …

Keratinocytic cancers (KCs), specifically cutaneous squamous cell and basal cell
carcinomas, can respond to topical, intralesional, or systemic immunotherapies, but …

Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized
by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have become a mainstay of
oncologic treatment over the past decade. There are currently 11 ICIs approved by the US …

A 72-year-old man with multiple prior head and neck skin cancers presented with 8 months
of facial erosions. He had received excision, radiation therapy, and carboplatin/paclitaxel for …